APPLICATION
ANDA207684
TYPE
ANDA
ORIGINAL APPROVAL
2017-08-03
LATEST ACTION
2018-12-21
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription
Products
NEVIRAPINEPrescription
NEVIRAPINE 50MG/5ML · SUSPENSION · ORAL
Approval history
2018-12-21Labeling · Supplement 1 · standardAP
2017-08-03UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.